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Purpose: Most classical aniridia is caused by PAX6 haploinsuffi-
ciency. PAX6 missense variants can be hypomorphic or mimic
haploinsufficiency. We hypothesized that missense variants also
cause previously undescribed disease by altering the affinity and/or
specificity of PAX6 genomic interactions.
Methods: We screened PAX6 in 372 individuals with bilateral
microphthalmia, anophthalmia, or coloboma (MAC) from the
Medical Research Council Human Genetics Unit eye malformation
cohort (HGUeye) and reviewed data from the Deciphering
Developmental Disorders study. We performed cluster analysis
on PAX6-associated ocular phenotypes by variant type and
molecular modeling of the structural impact of 86 different PAX6
causative missense variants.
Results: Eight different PAX6 missense variants were identified in
17 individuals (15 families) with MAC, accounting for 4% (15/372)
of our cohort. Seven altered the paired domain (p.[Arg26Gln]x1,
p.[Gly36Val]x1, p.[Arg38Trp]x2, p.[Arg38Gln]x1, p.[Gly51Arg]x2,
p.[Ser54Arg]x2, p.[Asn124Lys]x5) and one the homeodomain
(p.[Asn260Tyr]x1). p.Ser54Arg and p.Asn124Lys were exclusively
associated with severe bilateral microphthalmia. MAC-associated
variants were predicted to alter but not ablate DNA interaction,
consistent with the electrophoretic mobility shifts observed using
mutant paired domains with well-characterized PAX6-binding
sites. We found no strong evidence for novel PAX6-associated
extraocular disease.
Conclusion: Altering the affinity and specificity of PAX6-binding
genome-wide provides a plausible mechanism for the worse-than-
null effects of MAC-associated missense variants.
Genetics in Medicine (2019) https://doi.org/10.1038/s41436-019-
0685-9
Keywords: PAX6; missense variant; paired domain; micro-
phthalmia; protein destabilization
INTRODUCTION
Classical aniridia (MIM 106210) is typified by absence or
severe hypoplasia of the iris associated with cataracts,
keratopathy, glaucoma, foveal hypoplasia, and optic nerve
malformations, and absence or hypoplasia of the anterior
commissure, olfactory bulb, and pineal gland.1 It is almost
exclusively caused by genomic variants that result in
haploinsufficiency of PAX6, by gene deletion, cis-regulatory
variant, or likely/presumed gene disruptive (LGD) variants.
PAX6missense variants may mimic haploinsufficiency but are
more commonly associated with milder phenotypes, such as
partial aniridia, ectopia pupillae (MIM 129750), isolated
foveal hypoplasia (MIM 136520), Peters anomaly (MIM
604229), or optic disc malformations.2–4 Compound hetero-
zygous LGD variants of PAX6 are a rare cause of syndromic
bilateral anophthalmia (absent eyes) associated with severe
brain and craniofacial defects.5,6
PAX6 (MIM 607108) encodes a transcription factor essential
for the correct development of the eye, central nervous system,
and pancreas, and for maintenance of these tissues in
adulthood.7–10 PAX6 binds DNA via two highly conserved
DNA-binding domains: a homeodomain (HD) and a
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structurally bipartite paired domain (PD) with N-terminal
(NTS) and C-terminal (CTS) subdomains, each containing
three α-helices that incorporate a helix–turn–helix motif. Each
subdomain can independently or cooperatively bind DNA, and
can modulate the DNA-binding properties of the HD.11
The diverse range of sequences that mediate binding of PAX6
to the genome have been defined using chromatin immuno-
precipitation (ChIP)12 and, subsequently, hidden Markov
modeling using experimentally derived binding sites with
evolutionary conservation of the bound sequences to enrich
for truly functional elements.13 These approaches have identified
between 600 (ref. 13) and ~2500 (ref. 12) high-confidence
functional binding sites controlling between 90 (ref. 12) and 200
(ref. 12,13) different genes. The quaternary structure of the
interaction of the PAX6 paired domain with a specific binding
site has been determined using X-ray crystallography.14 PAX6
has been shown to bind cooperatively with SOX2 in vitro.15
Heterozygous LGD variants in SOX2 are the most common
cause of severe bilateral eye malformations.16
Here we use an unbiased approach to define the
phenotypic spectrum associated with PAX6 missense variants
and determine how confidently the observed phenotype can
be predicted by the nature and position of each causative
amino acid substitution and their predicted impact on DNA
binding. To define the ocular phenotypic spectrum we
reviewed all of the published cases of PAX6 missense variants
and those identified in the HGUeye cohort, which is enriched
for severe eye malformations, particularly microphthalmia,
anophthalmia, and coloboma (MAC). To look for previously
undescribed extraocular phenotypes we reviewed all of the
likely causative PAX6 missense variants reported in the
Deciphering Developmental Disorders (DDD) study,17,18
which has performed exome sequencing on 6993 individuals
with previously undiagnosed, diverse, and severe develop-
mental disorders with adequate phenotypic data.
MATERIALS AND METHODS
Ethical approval
This study complied with the tenets of the Declaration of
Helsinki: informed consent was obtained from all of the
families, including permission to publish patient photos. The
Medical Research Council (MRC) Human Genetics Unit eye
malformation (HGUeye) cohort was collected and maintained
using protocols approved by the Scotland UK Multicentre
Research Ethics Committee: 06/MRE00/76 “Linkage and
mutation analysis of developmental eye genes in cases of
severe structural eye malformations” and 16/SS/0201 “An
investigation of the genetic causes of human eye malforma-
tions.” The Deciphering Developmental Disorders (DDD)
Study was collected under a protocol approved by Cambridge
UK Multicentre Research Ethics Committee: 10/H0305/83
“The Deciphering Developmental Disorders Study.”
Variant analysis
Missense variants from the HGUeye cohort were identified by
a variety of different methods used to perform variant analysis
of the PAX6 coding sequence from genomic DNA, including
heteroduplex analyses, Sanger sequencing, and targeted next-
generation sequencing (including exome sequencing), essen-
tially as described.19 PAX6 missense variants in the DDD
study (www.ddduk.org), identified from trio based exome
sequencing and diagnostic filtering of the variants, was
performed as described.17,18 Targeted sequencing of indivi-
duals with foveal hypoplasia was performed in the Salisbury
NHS Foundation Trust genetic testing program. We desig-
nated PAX6 missense variants present in the gnomAD
database v.2.1 (https://gnomad.broadinstitute.org/gene/
ENSG00000007372/transcript/ENST00000379132) as puta-
tively benign for the purposes of comparison with the
pathogenic variants. All variants were numbered according
to the reference sequences NC_000011.10 (genomic,
GRCh38), NM_000280.4; ENST00000379132 (transcript,
1269 nucleotides open reading frame), and NP_000271.1;
P26367-1; LRG_720p1; ENSP00000492315.1 (isoform, 422
amino acids).
Phenotypic cluster analysis
Nonredundant components of the ocular phenotype were
systematically coded in individuals with PAX6 missense
variants and compared with those from a size-matched
random sample of individuals with PAX6 LGD variants
(Table S1). The phenotypic data were curated from original
publications, and/or from the original clinical descriptions
from the referring clinicians. The clustering analyses and
generation of the heat maps were performed using the
R packages cluster and gplots, and the function heatmap.2
(see Table S1 for further details of the phenotyping and
scripting). Within heatmap.2, the functions dist and daisy
were combined to compute the distance/dissimilarity
matrix, respectively (combining the two allowed missing
data, NA, to be taken into account in the clustering).
Euclidean distance (root sum-of-squares of differences) was
selected as the metric argument within daisy. When
Manhattan distances (sum of absolute differences) were
selected as an argument, the heat map did not change
significantly (Fig. S1a).
Computational modeling and phenotype predictions
All structural analyses used the X-ray crystal structure of the
DNA-bound PD (PDB ID: 6pax) and a homology model of
the DNA-bound HD, built with SWISS-MODEL20 using the
crystal structure of the closely related Drosophila Aristaless
HD (PDB ID: 3lnq) as a template. The effects of all missense
variants were modeled with the program FoldX,21 both using
the protein monomer by itself and the protein:DNA complex.
Default FoldX parameters were used, with ten replicates
performed per variant. Variants with ΔΔG > 1.6 kcal/mol
(using the same threshold described previously22) for the
protein monomer were classified as “destabilize folding.”
Variants with monomer ΔΔG ≤ 1.6 kcal/mol, where the
difference between the ΔΔG for the full complex and the
monomer was >0.25 kcal/mol, were classified as “perturb
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protein:DNA interaction.” All other variants were classified as
“unknown molecular effect.”
In total, 21 different computational phenotype predictors
were run for all of the pathogenic and putatively benign
(gnomAD) variants in the primary PAX6 isoform (Uniprot
ID: P26367). The predicted properties of all variants are
provided in Table S2.
To assess evolutionary conservation of PAX6 residues among
orthologous proteins, 124 sequences from Ensembl Compara
were used (https://www.ensembl.org/Homo_sapiens/Gene/
Compara_Ortholog?db=core;g=ENSG00000007372;r=11:31784
779-31818062).
Electrophoretic mobility shift assay (EMSA)
EMSA experiments were performed using purified PAX6 PD
protein variants and two known DNA target sequences. The
PAX6 PD was expressed from plasmid vector in pGEX-6P-1t and
site-directed mutagenesis was used to generate clones expressing
the variants p.Cys52Arg, p.Ser54Arg, p.Arg92Gln, p.Ser121Leu,
and p.Asn124Lys. The proteins were expressed as GST-fusion
proteins in E. coli BL21-Gold(DE3) Competent Cells (Agilent),
purified with Glutathione Sepharose 4B beads and cleaved using
PreScission cleavage enzyme. DNA target sequences were double-
stranded Fam-labeled oligos (Integrated DNA Technologies)
incorporating the PAX6 enhancer sequences LE9 or SIMO.
Reaction products were resolved on native PAGE gels and
densitometry performed using Image Studio Lite (LI-COR
Biosciences). Quantified binding of wild-type PAX6 PD was
fitted to the Hill equation (GraphPad Prism 8 software) to
calculate the Kd value, which was the concentration used for
comparison of the binding properties of each of the PAX6 PD
protein variants. Within each experiment, the proportion bound
was normalized to the wild type. One-way repeated-measures
analysis of variance (ANOVA) was used, with Dunnett’s multiple
comparison test to compare the protein–DNA binding of the
different protein variants versus the wild-type PAX6 PD. Alpha
was set at p= 0.05.
Identification of variants in PAX6 paralogs
Eight human paralogous members of the PAX family
(excluding PAX6) were selected to identify all pathogenic
missense variants in the PD of each protein. Variants were
identified using publicly available data from Alamut Visual
v2.11 (SOPHiA Genetics), including ClinVar (pathogenic,
likely pathogenic categories), and from Leiden Open Varia-
tion Database (LOVD) (http://www.lovd.nl/3.0/) and litera-
ture searching. All variants reported as pathogenic and with
phenotype details were collated and tabulated in text form
and as a component of a multiple sequence alignment
(CLUSTAL O1.2.4).
RESULTS
Defining the spectrum of ocular phenotypes associated
with PAX6 missense variants
To look for novel ocular phenotypes associated with PAX6
missense variants, we selected 372 individuals with bilateral
MAC from a total of 1169 unrelated screened individuals with
a wide spectrum of eye malformations in the HGUeye cohort
(Table S3). In this MAC group, 17 individuals from 15
families have eight different ultrarare, heterozygous PAX6
missense variants altering seven different residues (Table 1,
see Supplementary Materials and Methods for detailed clinical
descriptions). In six affected individuals the variant had
occurred de novo. In the two multiplex families the variant
segregated appropriately with the disease. In the remaining
seven affected individuals we were not able to determine the
inheritance of the causative allele because all of the required
samples were not available. Of the seven substituted residues
in the MAC group, six were within the PD (Arg26, Gly36,
Arg38, Gly51, Ser54, Asn124) and one in the HD (Asn260).
Recurrent substitutions were seen in 4/6 PD residues,
involving either identical (p.Arg38Trp, p.Gly51Arg, p.Ser54-
Arg, p.Asn124Lys) or different (p.Arg38Trp/Gln) amino
acids. All individuals with a p.Ser54Arg or p.Asn124Lys
variant were prescreened and found to be wild type for SOX2
and OTX2 coding sequences.
To identify missense variants that either mimic haploin-
sufficiency or represent likely hypomorphic alleles we took
two different approaches. First we selected a group of 399
unrelated individuals from the HGUeye cohort who were
strongly enriched for classical aniridia and other known
PAX6-associated ocular malformations. From this analysis,
seven non-MAC individuals from three families have two
different heterozygous missense variants, Val78Ala and
Arg128His, both of which are in the PD. The clinical features
of these individuals are summarized in Table 2. In addition,
we reviewed and tabulated phenotypic and genetic data on
PAX6 missense variants from other sources, including all
published cases that were accessible to us (Tables S1, S4),
resulting in a total of 161 affected individuals from 110
families with 86 different missense variants. As a “true
haploinsufficiency” comparison group, we extracted pheno-
typic information from a randomly selected matched number
of individuals with PAX6 LGD variants (Table S1).
Phenotypic cluster analysis identifies worse-than-null PAX6
missense variants
We used the detailed ocular phenotypic and genetics
information from the set of individuals identified in the
previous section to perform a cluster analysis to determine
whether missense and LGD variants in PAX6 could be
distinguished on the basis of their phenotypes. This
confirmed that aniridia is highly correlated with LGD
variants. MAC and anterior segment dysgenesis cluster
separately but are both correlated with missense variants
(Figs. 1a, S1). Ocular features that are highly correlated with
aniridia, such as foveal hypoplasia, cataract, and keratopathy,
are more evenly distributed between LGD and missense
variants. The individuals with p.Ser54Arg and p.Asn124Lys
variants were distinguishable as severe bilateral microphthal-
mia with or without iris defects, coloboma, congenital corneal
opacification, retinal detachment, and lens defects comprising
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Aniridia
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/Nystagmus
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hypoplasia
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Microphthalmia
-coloboma
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i. Patient ID 3189 c.160A>C p.(Ser54rg)
R L R L
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iii. Patient ID 1517 c.372C>A p.(Asn124Lys)
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vi. Patient ID 1016 c.113G>A p.(Arg38Gln)v. Patient ID 1139 c.77G>A p.(Arg26Gln)
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vii. Patient ID 4091 c.151G>A p.(Gly51Arg)
PAX6 4 130 210 269
a
b
Fig. 1 Computational clustering and severity of PAX6-associated phenotypes. (a) Quantitative phenotype-driven clustering analysis. The ocular
features assessed are labeled on the x-axis. Variants encoded by pathogenic PAX6 missense variants (blue; n= 161) and a size-matched cohort of likely/
presumed gene disruptive (LGD) variants (black; nonsense and frameshift variants with predicted nonsense-mediated decay) were clustered according to
phenotypic features using the R packages cluster and gplots, and the function heatmap.2 (red/dark red, feature present; gray, feature absent; white, data
not available). The clustering reveals that LGD variants are predominantly associated with classical aniridia features, whereas missense variants have a
wider phenotypic spectrum that includes distinct clusters of microphthalmia, anophthalmia, or coloboma (MAC) spectrum and anterior segment
dysgenesis phenotypes. The aniridia-associated features foveal hypoplasia, cataract, and keratopathy, which can present in the absence of iris defects,
are more evenly distributed across both classes of variants. Detailed versions of the phenotyping data set used for the clustering analysis and the heat
map, with all of the missense and LGD variants labeled, are available (Table S1 and Fig. S1, respectively). (b) SOX2-like phenotype associated with
recurrent PAX6 p.Ser54Arg and p.Asn124Lys variants. A schematic of PAX6 isoform NP_000271.1 (P26367-1, 422 amino acids) indicating the position of
the paired domain (PD; red box), homeodomain (HD; green box), the alternatively spliced 14 amino acids (yellow box) that are present in the PAX6+ 5a
isoform NP_001595.2 (P26367-2, 436 amino acids), and the PAX6 coding exon boundaries (white vertical bars). The PD-HD linker region and the
C-terminal transregulatory region are labeled. Images i–iv, shown above the schematic, are the eye phenotypes of HGUeye cohort MAC individuals with
PAX6 p.(Ser54Arg) or p.(Asn124Lys) PD variants, which are recurrent and uniquely associated with severe bilateral defects; v–vii, shown below the
schematic, are the eye phenotypes of HGUeye cohort MAC individuals with PAX6 PD (NTS) variants, which are recurrent and are associated with more
variable phenotypes; v(F), fundus image of patient ID 1139 with bilateral choroidal coloboma; vii’, magnetic resonance image (MRI) showing bilateral mild
microphthalmia in patient ID 4091. L left eye, R right eye.
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primary aphakia, reduced size, and subluxation (Fig. 1b). This
constellation is reminiscent of the ocular features associated
with SOX2 variants (MIM 184429).23
Protein structural analysis reveals that PAX6 variants that
affect DNA binding are highly associated with
microphthalmia
In an attempt to understand the molecular basis underlying
the MAC-associated PAX6 missense variants, we investigated
their protein structural context. In total, 22/86 missense
variants (32/161 affected individuals) were classified as MAC-
associated in the phenotypic cluster analysis. Overall, both
MAC and non-MAC variants occur throughout both halves
of the PD and in the HD, and there is no obvious clustering of
the MAC variants in three-dimensional space (Fig. 2a;
stratified further by phenotype in Fig. S2). Ser54 and Asn124,
located in helices αIII of the NTS and αVI of the CTS,
both make substantial contacts with DNA, burying 44.3 and
51.8 Å2 of surface area, respectively.
Next, we used the molecular modeling program FoldX21 to
predict the effects of PAX6 missense variants. FoldX was
previously shown to be useful for identifying PAX6 variants
that disrupt folding or interactions with DNA.22 We classified
all 86 pathogenic variants into three categories: those
predicted to be highly destabilizing to protein structure and
disrupt protein folding (n= 35), those predicted to perturb
the interaction with DNA (n= 22), and those of unknown
molecular effect (n= 29). Interestingly, more than half (12/
22) of the MAC variants were predicted to affect the
interaction with DNA, compared with only 10/64 non-MAC
αIII αIV αV αVI
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variants (Fig. 2b). Moreover, only 1/22 MAC variants (36
individuals with MAC) had an unknown molecular effect,
compared with 28/64 non-MAC variants (125 individuals
with non-MAC). Other phenotypic categories showed no
significant differences in their association with variants
predicted to affect protein folding or DNA binding (Fig. S3,
Table S2).
We also investigated the ability of many existing sequence-
based phenotype predictors to identify pathogenic PAX6
missense variants (Table S5). None of them shows any
significant ability to distinguish MAC from non-MAC
variants. However, many perform very well at discriminating
the pathogenic PAX6 missense variants from 121 putatively
benign variants present in the gnomAD database. Interest-
ingly, FoldX, which uses structure alone, is competitive with
the top-ranking predictors, which rely mostly on evolutionary
conservation, demonstrating the power of protein structure
for predicting both the pathogenicity and phenotype of PAX6
missense variants.
EMSA characterization of variant interactions with known
PAX6-binding sites
As the structural analysis suggests that many PAX6 variants
are likely to affect the interaction of the PD with DNA, we
used EMSA experiments to test a subset of variants for their
binding to two well-characterized PAX6-binding sites: the
LE9 and SIMO elements24,25 (Figs. 2c, S4). One of the severe
MAC-associated variants, p.Ser54Arg, caused an 85% reduc-
tion in binding to LE9 but had no effect on SIMO binding,
while p.Asn124Lys showed reduced binding to both (42% to
LE9, 62% to SIMO). In contrast, the classical aniridia variants
p.Cys52Arg26 and p.Ser121Leu27 both completely disrupted
binding to SIMO and caused an 80–90% disruption of
binding to LE9. We also tested p.Arg92Gln (rs769095184),
which was presumed to be a neutral variant because it was
present in eight individuals (East Asian, allele frequency
0.0004349) in gnomAD. It showed a LE9 and SIMO binding
pattern very similar to p.Asn124Lys, which was initially
surprising, but consistent with the fact that it is predicted by
our structural analysis to moderately perturb the interaction
with DNA. Interestingly, this variant was very recently
reported, with limited segregation details, as being associated
with classical aniridia in a Chinese family with four affected
individuals.28
PAX6 missense variants as a cause of previously
undescribed nonocular phenotypes
Finally, to determine whether PAX6 missense variants may
cause previously undescribed conditions with significant
extraocular effects, we examined the phenotypes of indivi-
duals in the DDD cohort.17,18 Seven individuals had six
different ultrarare, heterozygous PAX6 missense variants
(Table 3). Four individuals with structural eye anomalies
had three different missense variants in the PD (p.[Arg26Gly]
x2, p.[Arg26Gln]x1, p.[Gly64Ala]x1). The two different Arg26
variants are recurrent (see Table 1 and ref. 29). The remaining
three individuals had either predominantly neurological
phenotypes or multiple nonocular malformations. Two
variants occur in the PD (p.Glu62Val and p.Ile117Thr) and
are predicted to be mild at a structural level and not
significantly perturb protein folding or the interaction with
DNA. The other (p.Gln201His) is in the flexible linker
between the PD and HD and is not particularly close to any
known pathogenic variants. Interestingly, the three top-
ranking computational phenotype predictors (FATHMM,
M-CAP, and DeepSequence) are supportive of pathogenicity
Fig. 2 Protein structural analysis, DNA interaction, and paralog comparison of PAX6 variants. (a) Protein structural analysis of microphthalmia,
anophthalmia, or coloboma (MAC) versus non-MAC missense variants. Locations of pathogenic missense variants highlighted on the structures of the DNA-
binding domains: paired domain (PD) (PDB ID: 6pax) and homeodomain (HD) (homology model of the complex based upon PDB ID: 3lnq). Residues mutated
in individuals with MAC are shown in red, while all other residues associated with pathogenic variants are shown in light blue. Figure S2 shows the variants
further stratified by phenotype, and also shows other nonpathogenic variants from gnomAD observed in the human population. (b) Predicted molecular
effects of MAC versus non-MAC missense variants. The P value is calculated with Fisher’s exact test, based upon the proportion of variants in each group of
unknown molecular effect. (c) Effect of PD missense variants on binding to known DNA targets of PAX6. Electrophoretic mobility shift assays (EMSA) of the
PD of PAX6. Two known DNA targets of the PAX6 PD, the LE9 and SIMO enhancer elements, were selected as binding sequences. For each element, the
DNA binding of wild-type PD (lane 2 of each gel image) was compared with five different mutant PDs: Cys52Arg and Ser121Leu (C52R and S121L, aniridia-
associated variants, lanes 3 and 6 of each gel image), Ser54Arg and Asn124Lys (S54R and N124K, MAC-associated variants, lanes 4 and 7 of each gel
image), and Arg92Gln (R92Q, gnomAD variant, lane 5 of each gel image). For the MAC-associated variants, PD-Ser54Arg showed reduced binding to the
LE9 element (left panel) but not to the SIMO element (right panel), whereas PD-Asn124Lys showed a moderate reduction in binding to both the LE9 and
SIMO elements (left and right panels, respectively). Quantification data of the wild-type and mutant PD binding profiles are shown above each repre-
sentative EMSA gel image: black, wild-type PD normalized binding; red, C52R and S121L aniridia-associated variants; purple, S45R and N124K MAC-
associated variants; blue, R92Q gnomAD variant. (d) Comparison of disease-associated PD variants in PAX6 paralogs. A multiple sequence alignment
(generated by CLUSTAL O1.2.4) showing the PD of the nine members of the PAX protein family: PAX1/9, PAX2/5/8, PAX3/7, and PAX4/6. Gray shaded
blocks, α-helices αI–αIII of the N-terminal subdomain; green shaded blocks, α-helices αIV–αVI of the C-terminal subdomain; red bold, residues with
pathogenic PAX6 missense variants identified in the HGUeye MAC (blue shaded), non-MAC (yellow shaded), and Deciphering Developmental Disorders
(DDD) (black underlined) cohorts analyzed in this report or conserved at these positions across the protein family (unshaded); brown shaded box, residues
with previously reported pathogenic missense variants (for PAX6 these are restricted to those associated with MAC phenotypes). Residues associated with
MAC cases in this report are labeled below the alignment, indicating the residue number and in brackets the number of unrelated cases with a missense
variant; PAX6 Ser54 and Asn124, the residues uniquely associated with severe MAC phenotypes, are shown in bold. An extended version of this figure,
detailing the reported pathogenic missense variants in the HD of PAX3/7 and PAX 4/6, is available (Fig. S6). CTS C-terminal subdomain, NTS N-terminal
subdomain, WT wild type.
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for the two PD variants, having values similar to other
pathogenic PAX6 variants and distinct from most of the
variants in gnomAD (Fig. S5). Overall, however, we found no
clear evidence for major nonocular developmental defects due
to PAX6 missense variants.
DISCUSSION
The extraordinary, almost one-to-one, association of typical
aniridia to heterozygous loss-of-function PAX6 variants
understandably dominates the human disease literature
associated with this gene. Over many years, the MRC Human
Genetics Unit has established a large research cohort of
individuals with aniridia and other severe eye malformations
that have been screened for causative variants in PAX6. This,
together with the availability of phenotypic and trio exome
sequencing data from the DDD study, has allowed us to use
multiple independent approaches to define the phenotypic
spectrum associated with missense variants in PAX6. This has
identified a specific subset of heterozygous missense variants
in the PAX6 DNA-binding domains that are associated with
severe bilateral microphthalmia, most notably the recurrent
substitutions of Ser54 and Asn124 within the PD.
It has been inferred that the PD arose from gene duplication
of a three-helix unit, with divergent evolution resulting in the
NTS and CTS losing amino acid and DNA target sequence
similarity but maintaining a twofold pseudosymmetry axis that
permits similar folding and docking of each subdomain into the
major groove of double-stranded DNA (dsDNA). In this regard,
it is interesting to note that both Ser54 and Asn124 occur at
approximately equivalent positions within their subdomains
and both make direct contacts with the major groove, with
similar relative positioning in the 5’ and 3’ regions of the DNA
target binding site (Fig. 2a). Ser54 is conserved in all members
of the human PAX family, and Asn124 in PAX2/5/8 and PAX4/
6 (Figs. 2d, S6). In PAX6 orthologues, Ser54 is invariant, and
Asn124 is conserved in all but two avian species.
The severe bilateral microphthalmia phenotypic spectrum
associated with p.Ser54Arg and p.Asn124Lys is similar to that
associated with SOX2 variants (MIM 184429).23 There are
several reasons this is an important observation. SOX2 is a
lineage-specific transcription factor, which cobinds with Pax6
to the promoter elements of many genes in presumptive lens
cells.30,31 In chicken, PAX6 and SOX2 cooperatively interact
at the lens-specific DC5 enhancer of delta crystallin and the
N-3 enhancer of Sox2.32,33 In an optic cup progenitor cell-
conditional Sox2-deficient mouse model, the severe ocular
defects, including extreme microphthalmia, are ameliorated
when crossed onto a Pax6-haploinsufficient background.34
These data suggest that the transcriptional activation profiles
of PAX6 and SOX2 are tightly regulated and can be
interdependent, and therefore that the perturbation of the
transcriptional activity of either gene can cause severe ocular
defects during development. It is possible that the individuals
with severe bilateral MAC and a PAX6 variant also carry an
as-yet-unidentified variant in a regulatory region or upstream
regulator of SOX2. However, this seems unlikely, given the
number and recurrent nature of the PAX6 variants identified
in the HGUeye cohort. The other important factor being that
both p.Ser54Arg and all but two of the p.Asn124Lys variants
occurred de novo in the affected individuals (in two adult
cases inheritance could not be determined). This strongly
supports monoallelic variants in PAX6 as the cause of the
severe bilateral microphthalmia.
One individual, with a phenotype similar to that associated
with the recurrent p.Ser54Arg and p.Asn124Lys changes, has
a variant in the HD (p.Asn260Tyr). Asn260 is invariant in all
paired-type HDs and is adjacent to the C-terminal basic
cluster (residues 261–267) component of the PAX6 HD
nuclear localization signal (Fig. S6). In zebrafish Pax6 this
asparagine is critical for binding DNA target sequences and
for CTS–HD interaction.35 The two previously reported
MAC-associated HD variants similarly substitute conserved
residues in the recognition helix, Val256 and Phe258, and
cause iris defects and severe bilateral phenotypes including
microphthalmia with primary aphakia or chorioretinal and
optic nerve coloboma.3,36 A recently reported case with p.
Arg261Gly had congenital cataract and a family history of
coloboma.37 HD recognition helix variants are reported for
PAX3 in association with Waardenburg syndrome type 1, and
for PAX7 in a single case of cleft lip and palate (Fig. S6).38,39
Taken together, the results of the protein structural analysis
and EMSA experiments have allowed us to develop
hypotheses regarding the worse-than-null phenotypes we
observed. The most severe MAC-associated variants perturb
the interaction of any one of the three DNA-binding (sub)
domains. We infer that DNA binding is unlikely to be
completely abrogated as the two remaining wild-type (sub)
domains are sufficient for DNA interaction. However, both
the affinity of these interactions and the location of bound
sites are likely to be altered. The remarkable sequence
diversity of in vivo PAX6-binding sites12,13 would predict
variant-specific differential effects on both the degree and
repertoire of target gene activation. In contrast, the classical
aniridia variants tested experimentally retain almost no DNA-
binding activity, consistent with an altered dosage haploin-
sufficiency phenotype similar to the LGD variants. Impor-
tantly, however, these molecular properties alone cannot
explain all of the phenotypic heterogeneity observed among
PAX6 missense variants. This is highlighted by the fact that
there are several examples in our data set of different patients
with the same variant exhibiting very different phenotypes
(Table S4).
Four other members of the PAX gene family are associated
with robust pathogenic missense variants in the PD (Fig. 2d;
see Fig. S6, Table S6 for further details). These include PAX2
(papillorenal syndrome and focal segmental glomerulosclero-
sis 7; MIM 120330 and 616002), PAX3 (Waardenburg
syndrome type I and type 3 and craniofacial–deafness–hand
syndrome; MIM 193500, 148820, and 122880), PAX8
(congenital nongoitrous hypothyroidism; MIM 218700) and
PAX9 (tooth agenesis; MIM 604625). Of the eight residues
that have causative substitutions detailed above in HGUeye
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MAC or DDD, seven are invariant across the paralogs.
Asn124 is conserved only in PAX2, PAX5, and PAX8 (group
II) and PAX4 (group IV); no disease-associated missense
variants have been reported at this position. Six of the seven
invariant residues have causative missense variants reported
in PAX6 paralogs. For Ser54 a different substitution at the
equivalent residue in PAX3 (p.Ser84Phe) has been reported in
a single family (Table S6). Heterozygosity for this variant was
not associated with a worse-than-null phenotype. Overall, of
the 44 different PAX6 PD positions with pathogenic variants,
25 have pathogenic variants at equivalent positions in
paralogous PAX genes. Furthermore, there are 24 PD residues
with pathogenic missense variants in paralogs with no known
pathogenic variants in PAX6; there is a high probability that
these could be the sites of pathogenic PAX6 variants to be
discovered in the future.
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